Literature DB >> 9201248

A practical prognostic index for inoperable non-small-cell lung cancer.

T Wigren1, H Oksanen, P Kellokumpu-Lehtinen.   

Abstract

Radical radiotherapy is widely used to treat inoperable non-small-cell lung cancer (NSCLC) although only a small number of patients benefit in the long run from this intensive treatment. There is a small proportion of long-term survivors who might derive advantage from even more aggressive radiotherapy combined with chemotherapy. In order to support optimal treatment selection we have carried out univariate and multivariate analyses of possible prognostic variables in the retrospective data of 502 NSCLC patients treated at one institute with external radiotherapy, both with curative and palliative intent. To obtain more accurate tools for a rational treatment decision, we identified, by using Cox's proportional-hazards model, the five most powerful determinants of overall survival and combined them to a prognostic index. On the basis of only the number of these risk factors (advanced stage, general or metastatic symptoms, poor performance status, anemia and tumor size of at least 7 cm), the patient falls into one of the six possible prognostic groups and these groups turned out to be identifiable as separate prognostic clusters. Thirty-one per cent of the patients have three or more risk factors and a median survival of 5-7 months compared with 18 months for patients without any non-favorable factor. Furthermore, the prognostic factors were so strong that multivariate analyses did not reveal the treatment selection to have any significant influence on survival. As each of the five variables have the advantage of being routinely available, our index is simple enough to be used in daily clinical practice. The clinical value of the prognostic index should be verified by using independent data.

Entities:  

Mesh:

Year:  1997        PMID: 9201248     DOI: 10.1007/bf01208636

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  Flow cytometric analysis of tumour DNA profile related to response to radiotherapy and survival in inoperable lung cancer.

Authors:  A Ojala; O P Kallioniemi; T Wigren; A Kallioniemi; J Mattila; M Lehtinen; T Koivula
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

2.  Blood analyses as prognostic factors in primary lung cancer.

Authors:  T Engan; E Hannisdal
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

3.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Authors:  J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

4.  Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

Authors:  C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman
Journal:  Cancer       Date:  1987-06-01       Impact factor: 6.860

5.  Small-cell carcinoma of the lung: derivation of a prognostic staging system.

Authors:  U Sagman; E Maki; W K Evans; D Warr; F A Shepherd; J P Sculier; R Haddad; D Payne; J F Pringle; J L Yeoh
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

6.  Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis.

Authors:  J L Pater; M Loeb
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

7.  The use of discriminant analysis to guide palliative treatment for lung cancer patients.

Authors:  J Thorogood; A S Bulman; T Collins; D Ash
Journal:  Clin Oncol (R Coll Radiol)       Date:  1992-01       Impact factor: 4.126

8.  Radical radiotherapy of inoperable non-small cell lung cancer. Irradiation techniques and tumor characteristics in relation to local control and survival.

Authors:  T Wigren; P Kellokumpu-Lehtinen; A Ojala
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

9.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.

Authors:  B Jeremic; Y Shibamoto; L Acimovic; L Djuric
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy.

Authors:  V Coen; M Van Lancker; W De Neve; G Storme
Journal:  Am J Clin Oncol       Date:  1995-04       Impact factor: 2.339

View more
  5 in total

1.  Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.

Authors:  Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

2.  [Survival time of exclusively irradiated NSCLC patients: the viewpoint of a clinical biologist. Concerning the article by R. Wilhelm et al in Strahlenther Onkol 1988: 174:128-32 (No. 3)].

Authors:  J Watine; R Fintelmann; J C Charet
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

3.  [Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level].

Authors:  R Wilhelm; G Kovács; D Heinrichsohn; R Galalae; B Kimmig
Journal:  Strahlenther Onkol       Date:  1998-03       Impact factor: 3.621

4.  A new scoring system for predicting survival in patients with non-small cell lung cancer.

Authors:  Steven E Schild; Angelina D Tan; Jason A Wampfler; Helen J Ross; Ping Yang; Jeff A Sloan
Journal:  Cancer Med       Date:  2015-06-23       Impact factor: 4.452

5.  The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.

Authors:  Yaqi Huang; Siqi Wei; Nan Jiang; Lijuan Zhang; Siyuan Wang; Xiaona Cao; Yue Zhao; Peiguo Wang
Journal:  BMC Cancer       Date:  2018-12-10       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.